RET and neoplasm: In the current landscape of potent RET-specific inhibitors, the demonstration of the high frequency of RET mutations, along with the importance of the Ras–MAPK pathway in tumor development and growth (93.3% of the tumors analyzed had driver variants observed in this pathway), solidifies the importance of tumor somatic analysis to identify the best therapeutic modality for young patients with advanced disease.